The global PDX models market is projected to reach USD 167.6 million by 2022 from USD 77.4 million in 2017, at a CAGR of 16.7%. Factors such as growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry are expected to drive the market in the coming years.
On the basis of type, the PDX models market is
segmented into mice models, and rat models. The rat models segment is expected
to grow at the highest CAGR of the global PDX models market in 2017. Growth in
this market is mainly driven by the larger size of rats, which enhances
surgical manipulation. Moreover, the development of immunodeficient rats will
further drive the usage of rat models in PDX model generation.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
Based on tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the respiratory tumor models segment, is expected to be the fastest-growing segment during the forecast period. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment as lung cancer is the leading cause of cancer-related deaths across the globe.
Geographically, the PDX models market in the
Asia Pacific region is expected to register the highest CAGR during the
forecast period. Growth in this regional segment is due to factors such as strong
research expenditure and the well-structured CRO industry in China, growth in
biomedical & medical research in Japan, rising pharmaceutical R&D
expenditure in India, and rising translational and biomedical research in
Singapore.
As compared to mature markets
such as the US and Europe, emerging markets such as China and Japan are
expected to provide significant growth opportunities to companies operating in
the PDX models market. The life sciences industry in these countries is robust
and is expected to contribute largely to the growth of the PDX models market in
the coming years. In addition, China has a strong focus on personalized
medicine coupled with a well structured CRO industry and growing focus of
pharmaceutical & animal research model suppliers.
Read more about PDX models market:
https://www.prnewswire.com/news-releases/patient-derived-xenograftpdx-models-market-worth-1676-million-usd-by-2022-683462071.html
